Additionally, extensive-stage SCLC patients could expect a significantly better prognosis with ICIs.Liu, and Liu SV and Rudin CM have demonstrated that the inclusion of PD-L1 inhibitor (atezolizumab) and PD-1 inhibitor (pembrolizumab) in chemotherapy can significantly extend overall survival (OS) compared to conventional chemotherapy (atezolizumab [HR=0.70, 95%CI 0.54–0.91, P=0.007] and pembrolizumab [HR=0.80, 95%CI 0.64–0.98, P=0.0164]) (4, 5). This evidence concerns the gene PDCD1 and small cell lung carcinoma.